Approaching 18 months of lecanemab and 6 months of donanemab in Japan: Key considerations for late-breaking insights

Key Points

• Key insights on the therapeutic interventions lecanemab and donanemab emerged after 18 and 6 months, respectively.
• The analysis highlights crucial biomarker changes observed in patients treated with these medications.
• Observational analysis reveals significant clinical implications for patients receiving lecanemab and donanemab in a Japanese healthcare setting.
• Understanding the impact of these therapies is essential for guiding future treatment protocols and optimizing patient care.